- Boston Institute of Biotechnology (BIB) receives the 2024 Global Biologics CDMO Technology Leadership Award from Frost & Sullivan.
- BIB’s breakthrough 30,000L bioreactor and Grand-CHO platform are driving advancements in biologics production and efficiency.
Boston Institute of Biotechnology (BIB) has been honoured with the 2024 Global Biologics CDMO Technology Leadership Award from Frost & Sullivan, recognising the company’s advancements in biologics manufacturing. This award celebrates BIB’s innovative contributions, including the world’s largest stainless steel bioreactor with a capacity of 30,000 litres, which is designed to meet the growing global demand for commercial-scale biologics production.
The biopharmaceutical industry faces increasing challenges in scaling production to meet demand, and traditional small-scale bioreactors have proven insufficient. To tackle this, BIB introduced a large-scale bioreactor that enhances scalability while reducing production costs to as low as $10 per gram, compared to the international average of hundreds of dollars per gram.
In addition to the bioreactor, BIB has developed its proprietary Grand-CHO platform, which integrates improvements in cell line development, process optimisation, and large-scale production. This platform has improved cell line stability and production yields, setting new industry standards. BIB’s Grand-CHO technology reduces production cycle times by 30% and enhances efficiency by doubling yield per fermentation volume.
